GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Valuation Rank

Nuvation Bio (Nuvation Bio) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Nuvation Bio Valuation Rank Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Valuation Rank
Comparable Companies
OVID OCUL EYPT VNDA AVIR VIGL XERS ACIU THRD IGMS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
NUVB:USA
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Website
https://www.nuvationbio.com
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).